EX-10.1






 Exhibit 10.1 

SERIES B PREFERRED 

STOCK PURCHASE AGREEMENT 

among 
 KIROMIC, INC. 

a Delaware corporation 
 and 

THE INVESTORS NAMED IN EXHIBIT A 

dated as of September 7, 2019 













 TABLE OF CONTENTS 

 

									
	 	 	 	 	 	  	Page	 
			
	1.	 	Purchase and Sale of Preferred Stock	  	 	1	 
		 	1.1	 	 Sale and Issuance of Preferred Stock
	  	 	1	 
		 	1.2	 	 Closing; Delivery
	  	 	1	 
		 	1.3	 	 Installments
	  	 	1	 
		 	1.4	 	 Sale of Additional Shares of Preferred Stock
	  	 	2	 
		 	1.5	 	 Use of Proceeds
	  	 	2	 
		 	1.6	 	 Defined Terms Used in this Agreement
	  	 	3	 
			
	2.	 	Representations and Warranties of the Company	  	 	3	 
		 	2.1	 	 Organization, Good Standing, Corporate Power and Qualification
	  	 	3	 
		 	2.2	 	 Capitalization
	  	 	3	 
		 	2.3	 	 Subsidiaries
	  	 	5	 
		 	2.4	 	 Authorization
	  	 	5	 
		 	2.5	 	 Valid Issuance of Shares
	  	 	5	 
		 	2.6	 	 Governmental Consents and Filings
	  	 	5	 
		 	2.7	 	 Litigation
	  	 	5	 
		 	2.8	 	 Intellectual Property
	  	 	6	 
		 	2.9	 	 Compliance with Other Instruments
	  	 	6	 
		 	2.10	 	 Agreements; Actions
	  	 	7	 
		 	2.11	 	 Certain Transactions
	  	 	7	 
		 	2.12	 	 Rights of Registration and Voting Rights
	  	 	8	 
		 	2.13	 	 Property
	  	 	8	 
		 	2.14	 	 Financial Statements
	  	 	8	 
		 	2.15	 	 Changes
	  	 	8	 
		 	2.16	 	 Employee Matters
	  	 	9	 
		 	2.17	 	 Tax Returns and Payments
	  	 	11	 
		 	2.18	 	 Insurance
	  	 	11	 
		 	2.19	 	 Employee Agreements
	  	 	11	 
		 	2.20	 	 Permits
	  	 	11	 
		 	2.21	 	 Corporate Documents
	  	 	11	 
		 	2.22	 	 Environmental and Safety Laws
	  	 	11	 
		 	2.23	 	 Disclosure
	  	 	12	 
		 	2.24	 	 Foreign Corrupt Practices Act
	  	 	12	 
			
	3.	 	Representations and Warranties of the Purchasers	  	 	12	 
		 	3.1	 	 Authorization
	  	 	13	 
		 	3.2	 	 Purchase Entirely for Own Account
	  	 	13	 
		 	3.3	 	 Disclosure of Information
	  	 	13	 
		 	3.4	 	 Restricted Securities
	  	 	13	 
		 	3.5	 	 No Public Market
	  	 	13	 
		 	3.6	 	 Legends
	  	 	13	 
		 	3.7	 	 Accredited Investor
	  	 	14	 
		 	3.8	 	 Foreign Investors
	  	 	14	 
		 	3.9	 	 No General Solicitation
	  	 	14	 


  
 i 















 TABLE OF CONTENTS 

(continued) 
  


									
	 	 	 	 	 	  	Page	 
		 	3.10	 	 Exculpation Among Purchasers
	  	 	14	 
		 	3.11	 	 Residence
	  	 	14	 
			
	4.	 	Conditions to the Purchasers’ Obligations at Closing	  	 	14	 
		 	4.1	 	 Representations and Warranties
	  	 	15	 
		 	4.2	 	 Performance
	  	 	15	 
		 	4.3	 	 Compliance Certificate
	  	 	15	 
		 	4.4	 	 Qualifications
	  	 	15	 
		 	4.5	 	 Board of Directors
	  	 	15	 
		 	4.6	 	 Investors’ Rights Agreement
	  	 	15	 
		 	4.7	 	 Right of First Refusal and Co-Sale Agreement
	  	 	15	 
		 	4.8	 	 Voting Agreement
	  	 	15	 
		 	4.9	 	 Restated Certificate
	  	 	15	 
		 	4.10	 	 Secretary’s Certificate
	  	 	15	 
		 	4.11	 	 Proceedings and Documents
	  	 	15	 
		 	4.12	 	 Preemptive Rights
	  	 	15	 
		 	4.13	 	 Warrant. Form of Warrant attached as Exhibit G
	  	 	16	 
			
	5.	 	Conditions of the Company’s Obligations at Closing	  	 	16	 
		 	5.1	 	 Representations and Warranties
	  	 	16	 
		 	5.2	 	 Performance
	  	 	16	 
		 	5.3	 	 Qualifications
	  	 	16	 
		 	5.4	 	 Investors’ Rights Agreement
	  	 	16	 
		 	5.5	 	 Right of First Refusal and Co-Sale Agreement
	  	 	16	 
		 	5.6	 	 Voting Agreement
	  	 	16	 
			
	6.	 	Miscellaneous	  	 	16	 
		 	6.1	 	 Survival of Warranties
	  	 	16	 
		 	6.2	 	 Successors and Assigns
	  	 	16	 
		 	6.3	 	 Governing Law
	  	 	16	 
		 	6.4	 	 Counterparts
	  	 	17	 
		 	6.5	 	 Titles and Subtitles
	  	 	17	 
		 	6.6	 	 Notices
	  	 	17	 
		 	6.7	 	 No Finder’s Fees
	  	 	18	 
		 	6.8	 	 Amendments and Waivers
	  	 	18	 
		 	6.9	 	 Severability
	  	 	18	 
		 	6.10	 	 Delays or Omissions
	  	 	18	 
		 	6.11	 	 Entire Agreement
	  	 	18	 
		 	6.12	 	 Termination of Closing Obligations
	  	 	18	 
		 	6.13	 	 Dispute Resolution
	  	 	19	 
		 	6.14	 	 No Commitment for Additional Financing
	  	 	19	 


									
				
		 	Exhibit A -	 	     SCHEDULE OF PURCHASERS
	  			
				
		 	Exhibit B -	 	     FORM OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION
	  			
				
		 	Exhibit C -	 	     DISCLOSURE SCHEDULE
	  			


  
 ii 















 TABLE OF CONTENTS 

(continued) 
  


									
	 	 	 	 	 	  	Page	 
				
		 	Exhibit D -	 	     FORM OF INVESTORS’ RIGHTS AGREEMENT
	  			
				
		 	Exhibit E -	 	     FORM OF RIGHT OF FIRST REFUSAL AND CO-SALE AGREEMENT
	  			
				
		 	Exhibit F -	 	     FORM OF VOTING AGREEMENT
	  			
				
		 	Exhibit G -	 	     FORM OF WARRANT
	  			


  
 iii 














 SERIES B PREFERRED STOCK PURCHASE AGREEMENT 

THIS SERIES B PREFERRED STOCK PURCHASE AGREEMENT (this “Agreement”), is made as of the      day of
                , 2019 by and among Kiromic, Inc., a Delaware corporation (the “Company”), the investors listed on Exhibit A attached to this
Agreement (each a “Purchaser” and together the “Purchasers”). 
 The parties hereby agree as follows: 

1.    Purchase and Sale of Preferred Stock. 

1.1    Sale and Issuance of Preferred Stock. 

(a)    The Company shall adopt and file with the Secretary of State of the State of Delaware on or before the Initial
Closing (as defined below) the Second Amended and Restated Certificate of Incorporation of the Company in the form of Exhibit B attached to this Agreement (the “Restated Certificate”). 

(b)    Subject to the terms and conditions of this Agreement, each Purchaser agrees to purchase at the Closing and the
Company agrees to sell and issue to each Purchaser at the Closing that number of shares of Series B Preferred Stock, $0.01 par value per share (the “Series B Preferred Stock”), set forth opposite each Purchaser’s name on
Exhibit A, at a purchase price of $0.46 per share. The shares of Series B Preferred Stock issued to the Purchasers pursuant to this Agreement (including any shares issued at the Initial Closing and any Additional Shares, as defined below)
shall be referred to in this Agreement as the “Shares.” 
 1.2    Closing; Delivery. 

(a)    The initial purchase and sale of the Shares shall take place remotely via the exchange of documents and
signatures, on the date first set forth above, or at such other time and place as the Company and the Purchasers mutually agree upon, orally or in writing (which time and place are designated as the “Initial Closing”). In the event
there is more than one closing, the term “Closing” shall apply to each such closing unless otherwise specified. 

(b)    At each Closing, the Company shall deliver to each Purchaser a certificate representing the Shares being purchased
by such Purchaser at such Closing against, as applicable: (i) payment of the purchase price therefor by check payable to the Company, by wire transfer to a bank account designated by the Company on the date of such Closing or (ii) payment
of the purchase price therefor in Installments (as defined below) as further described in Section 1.3, below. 

1.3    Installments 

(a)    The Company and certain Purchasers hereunder entered into a binding Letter Agreement dated as of August 21, 2019
pursuant to which, in relevant part, such Purchasers agreed to make and the Company agreed to receive payments in respect of the purchase price hereunder in accordance with a predetermined schedule (as reflected opposite each applicable
Purchaser’s name on Exhibit A) whereby the purchase price hereunder shall be paid incrementally in the amounts and on such dates as set forth on Exhibit A. 

1.4    Sale of Additional Shares of Preferred Stock. After the Initial Closing, the














 
Company may sell all or any portion of any authorized but unissued shares of Series B Preferred Stock (the “Additional Shares”), to one or more purchasers (the
“Additional Purchasers”), provided that (i) such subsequent sale is consummated prior to 90 days after the Initial Closing, (ii) each Additional Purchaser becomes a party to the Transaction Agreements (as defined below), by
executing and delivering a counterpart signature page to each of the Transaction Agreements. Exhibit A to this Agreement shall be updated to reflect the number of Additional Shares purchased at each such Closing and the parties purchasing such
Additional Shares. 
 1.5    Use of Proceeds. In accordance with the directions of the Company’s Board of
Directors, as it shall be constituted in accordance with the Voting Agreement, the Company will use the proceeds from the sale of the Shares only for: (i) legal fees, (ii) financial auditing fees, (iii) ordinary operational costs,
(iv) CRO or clinical site usage costs, (v) hiring employees or consultants, and (vi) costs incurred in connection with the preparation and filing of a registration statement with the United States Securities and Exchange Commission.

 1.6    Defined Terms Used in this Agreement. In addition to the terms defined above, the following terms used
in this Agreement shall be construed to have the meanings set forth or referenced below. 

(a)    “Affiliate” means, with respect to any specified Person, any other Person who, directly or
indirectly, controls, is controlled by, or is under common control with such Person, including, without limitation, any general partner, managing member, officer, director or trustee of such Person, or any venture capital fund or registered
investment company now or hereafter existing that is controlled by one or more general partners, managing members or investment advisers of, or shares the same management company or investment adviser with, such Person. 

(b)    “Code” means the Internal Revenue Code of 1986, as amended. 

(c)    “Company Intellectual Property” means all patents, patent applications, patent disclosures, and
all related continuation, continuation-in-part, divisional, reissue, reexamination, utility model, renewals, extensions, certificate of invention and design patents, patent applications, registrations and
applications for registrations, registered and unregistered trademarks, trademark applications, registered and unregistered service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and
proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the foregoing, tangible embodiments of any of the foregoing, licenses in, to and under any of the foregoing, and any and all such cases that
are owned or used by the Company in the conduct of the Company’s business as now conducted and as presently proposed to be conducted. 

(d)    “Investors’ Rights Agreement” means the agreement among the Company and the Purchasers and
certain other stockholders of the Company dated as of the date of the Initial Closing, in the form of Exhibit D attached to this Agreement. 

(e)    “Key Employee” means any executive-level employee as well as any employee or consultant who
either alone or in concert with others develops, invents, programs or designs any Company Intellectual Property. 

(f)    “Knowledge” including the phrase “to the Company’s knowledge” shall mean
the actual knowledge after reasonable investigation of the following officers: Maurizio Chiriva-Internati, Scott Dahlbeck, and Gianluca Rotino. 

  
 2 














 (g)    “Material Adverse Effect” means a material
adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property, or results of operations of the Company. 

(h)    “Person” means any individual, corporation, partnership, trust, limited liability company,
association or other entity. 
 (i)    “Purchaser” means each of the Purchasers who is initially a
party to this Agreement and any Additional Purchaser who becomes a party to this Agreement at a subsequent Closing under Subsection 1.2(b). 

(j)    “Right of First Refusal and Co-Sale Agreement” means the
agreement among the Company, the Purchasers, and certain other stockholders of the Company, dated as of the date of the Initial Closing, in the form of Exhibit E attached to this Agreement. 

(k)    “Securities Act” means the Securities Act of 1933, as amended, and the rules and regulations
promulgated thereunder. 
 (l)    “Shares” means the shares of Series B Preferred Stock issued at the
Initial Closing and any Additional Shares issued at a subsequent Closing under Subsection 1.2(b). 

(m)    “Transaction Agreements” means this Agreement, the Investors’ Rights Agreement, the Right of
First Refusal and Co-Sale Agreement, the Voting Agreement, and the Warrants. 

(n)    “Voting Agreement” means the agreement among the Company, the Purchasers and certain other
stockholders of the Company, dated as of the date of the Initial Closing, in the form of Exhibit F attached to this Agreement. 

2.    Representations and Warranties of the Company. The Company hereby represents and warrants to each Purchaser
that, except as set forth on the Disclosure Schedule attached as Exhibit C to this Agreement, which exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations are true and
complete as of the date of the Initial Closing, except as otherwise indicated. The Disclosure Schedule shall be arranged in sections corresponding to the numbered and lettered sections and subsections contained in this
Section 2, and the disclosures in any section or subsection of the Disclosure Schedule shall qualify other sections and subsections in this Section 2 only to the extent it is readily apparent from
a reading of the disclosure that such disclosure is applicable to such other sections and subsections. 
 For purposes of these
representations and warranties (other than those in Subsections 2.2, 2.3, 2.4, 2.5, and 2.6), the term the “Company” shall include any subsidiaries of the Company, unless otherwise noted herein.

 2.1    Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly
organized, validly existing and in good standing under the laws of the State of Delaware and has all requisite corporate power and authority to carry on its business as now conducted and as presently proposed to be conducted. The Company is duly
qualified to transact business and is in good standing in each jurisdiction in which the failure to so qualify would have a Material Adverse Effect. 

  
 3 














 2.2    Capitalization. 

(a)    The authorized capital of the Company will consist, immediately prior to the Initial Closing and upon acceptance
by the Secretary of State of Delaware of the Restated Certificate, of: 
 (i)    300,000,000 shares of common stock,
$0.0001 par value per share (the “Common Stock”), 100,000,000 shares of which are issued and outstanding immediately prior to the Initial Closing. All of the outstanding shares of Common Stock have been duly authorized, are fully
paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. 

(ii)    35,298,279 shares of Preferred Stock, (A) 21,167,844 shares of which are designated as Series A-1 Preferred Stock, all of which are issued and outstanding immediately prior to the Initial Closing, and (B) 14,130,435 shares of which are designated as Series B Preferred Stock, none of which are issued and
outstanding immediately prior to the Initial Closing. The rights, privileges and preferences of the Preferred Stock are as stated in the Restated Certificate and as provided by the Delaware General Corporation Law 

(b)    The Company has reserved 20,000,000 shares of Common Stock for issuance to officers, directors, employees and
consultants of the Company pursuant to its 2017 Equity Incentive Plan duly adopted by the Board of Directors and approved by the Company stockholders (the “Stock Plan”). Of such reserved shares of Common Stock, none have been issued
pursuant to restricted stock purchase agreements, options to purchase 19,060,484 shares have been granted and are currently outstanding, and 939,516 shares of Common Stock remain available for issuance to officers, directors, employees and
consultants pursuant to the Stock Plan. The Company has furnished to the Purchasers complete and accurate copies of the Stock Plan and forms of agreements used thereunder. 

(c)    Except for (A) the conversion privileges of the Shares to be issued under this Agreement, (B) the rights
provided in Section 4 of the Investors’ Rights Agreement, t and (D) the securities and rights described in Subsection 2.2(a)(ii) of this Agreement and Subsection 2.2(b) of the Disclosure Schedule, there are no outstanding
options, warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares of Common Stock or Series B Preferred Stock,
or any securities convertible into or exchangeable for shares of Common Stock or Series B Preferred Stock. All outstanding shares of the Company’s Common Stock and all shares of the Company’s Common Stock underlying outstanding options are
subject to (i) a right of first refusal in favor of the Company upon any proposed transfer (other than transfers for estate planning purposes); and (ii) a lock-up or market standoff agreement of not
less than one hundred eighty (180) days following the Company’s initial public offering pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act. 

(d)    None of the Company’s stock purchase agreements or stock option documents contains a provision for
acceleration of vesting (or lapse of a repurchase right) or other changes in the vesting provisions or other terms of such agreement or understanding upon the occurrence of any event or combination of events, including without limitation in the case
where the Company’s Stock Plan is not assumed in an acquisition. The Company has never adjusted or amended the exercise price of any stock options previously awarded, whether through amendment, cancellation, replacement grant, repricing, or any
other means. Except as set forth in the Restated Certificate, the Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital stock. 

(e)    The Company has obtained valid waivers of any rights by other parties to purchase any of the Shares covered by
this Agreement. 

  
 4 














 2.3    Subsidiaries. The Company does not currently own or
control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or
similar arrangement other than as set forth on Subsection 2.3 of the Disclosure Schedule. 

2.4    Authorization. All corporate action required to be taken by the Company’s Board of Directors and
stockholders in order to authorize the Company to enter into the Transaction Agreements, and to issue the Shares at the Closing and the Common Stock issuable upon conversion of the Shares, has been taken or will be taken prior to the Closing. All
action on the part of the officers of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of the Company under the Transaction Agreements to be performed as of the Closing, and the
issuance and delivery of the Shares has been taken or will be taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable
against the Company in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the
enforcement of creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained
in the Investors’ Rights Agreement and the Indemnification Agreement may be limited by applicable federal or state securities laws. 

2.5    Valid Issuance of Shares. The Shares, when issued, sold and delivered in accordance with the terms and for
the consideration set forth in this Agreement, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable state and federal securities
laws and liens or encumbrances created by or imposed by a Purchaser. Assuming the accuracy of the representations of the Purchasers in Section 3 of this Agreement and subject to the filings described in the Voting
Agreement, the Shares will be issued in compliance with all applicable federal and state securities laws. The Common Stock issuable upon conversion of the Shares has been duly reserved for issuance, and upon issuance in accordance with the terms of
the Restated Certificate, will be validly issued, fully paid and nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable federal and state securities laws and liens or
encumbrances created by or imposed by a Purchaser. Based in part upon the representations of the Purchasers in Section 3 of this Agreement and in the Voting Agreement, the Common Stock issuable upon conversion of the Shares
will be issued in compliance with all applicable federal and state securities laws. 
 2.6    Governmental Consents
and Filings. Assuming the accuracy of the representations made by the Purchasers in Section 3 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration
or filing with, any federal, state or local governmental authority is required on the part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for (i) the filing of the Restated
Certificate, which will have been filed as of the Initial Closing, and (ii) filings pursuant to Regulation D of the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner. 

2.7    Litigation. There is no known claim, action, suit, proceeding, arbitration, complaint, charge or
investigation pending or to the Company’s knowledge, currently threatened in writing: (i) against the Company or any officer, director or Key Employee of the Company arising out of their employment or board relationship with the Company;
(ii) to the Company’s knowledge, that questions the validity of the Transaction Agreements or the right of the Company to enter into them, or to consummate the transactions contemplated by the Transaction Agreements; or (iii) that
would reasonably 

  
 5 














 
be expected to have, either individually or in the aggregate, a Material Adverse Effect. Neither the Company nor, to the Company’s knowledge, any of its officers, directors or Key Employees
is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers, directors or Key Employees, such as would affect the Company).
There is no action, suit, proceeding or investigation by the Company pending or which the Company intends to initiate. The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any
basis therefor known to the Company) involving the prior employment of any of the Company’s employees, their services provided in connection with the Company’s business, any information or techniques allegedly proprietary to any of their
former employers or their obligations under any agreements with prior employers. 
 2.8    Intellectual Property.
The Company owns or possesses sufficient legal rights to all Company Intellectual Property without any known conflict with, or infringement of, the rights of others. To the Company’s knowledge, no product or service marketed or sold (or
proposed to be marketed or sold) by the Company violates or will violate any license or infringes or will infringe any intellectual property rights of any other party. Other than with respect to commercially available software products under
standard end-user object code license agreements, there are no outstanding options, licenses, agreements, claims, encumbrances or shared ownership interests of any kind relating to the Company Intellectual
Property, nor is the Company bound by or a party to any options, licenses or agreements of any kind with respect to the patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights and
processes of any other Person. The Company has not received any communications alleging that the Company has violated or, by conducting its business, would violate any of the patents, trademarks, service marks, tradenames, copyrights, trade secrets,
mask works or other proprietary rights or processes of any other Person. The Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or
leases or that it has otherwise provided to its employees for their use in connection with the Company’s business. To the Company’s knowledge, it will not be necessary to use any inventions of any of its employees or consultants (or
Persons it currently intends to hire) made prior to their employment by the Company. Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related to the Company’s business as now
conducted and as presently proposed to be conducted. Section 2.8 of the Disclosure Schedule lists all Company Intellectual Property. The Company has not embedded any open source, copyleft or community source code in any of its products
generally available or in development, including but not limited to any libraries or code licensed under any General Public License, Lesser General Public License or similar license arrangement. For purposes of this Section 2.8, the Company
shall be deemed to have knowledge of a patent right if the Company has actual knowledge of the patent right or would be found to be on notice of such patent right as determined by reference to United States patent laws. No government funding,
facilities of a university, college, other educational institution or research center, or funding from third parties was used in the development of any Company Intellectual Property. No Person who was involved in, or who contributed to, the creation
or development of any Company Intellectual Property, has performed services for the government, university, college, or other educational institution or research center in a manner that would affect Company’s rights in the Company Intellectual
Property. The Company is not subject to any restriction that requires or could require the Company’s products to be manufactured, produced or otherwise made in the United States. 

2.9    Compliance with Other Instruments. The Company is not in violation or default (i) of any provisions of
its Restated Certificate or Bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement, contract or purchase order to which it is a party or by
which it is bound that is required to be listed on the Disclosure Schedule, or (v) of any provision of federal or state statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect. The
execution, delivery and performance of 

  
 6 














 
the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in any such violation or be in conflict with or constitute, with or
without the passage of time and giving of notice, either (i) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement; or (ii) an event which results in the creation of any lien, charge or
encumbrance upon any assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company. 

2.10    Agreements; Actions. 

(a)    Except for the Transaction Agreements or as set forth on Subsection 2.10(a) of the Disclosure Schedules, there are
no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by which it is bound that involve (i) obligations (contingent or otherwise) of, or payments to, the Company in excess of $100,000,
(ii) the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company, (iii) the grant of rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that
limit the Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or (iv) indemnification by the Company with respect to infringements of proprietary rights. 

(b)    The Company has not (i) declared or paid any dividends, or authorized or made any distribution upon or with
respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred any other liabilities individually in excess of $100,000 or in excess of $250,000 in the aggregate, (iii) made any loans or
advances to any Person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. For the purposes of
(a) and (b) of this Subsection 2.10, all indebtedness, liabilities, agreements, understandings, instruments, contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe are
affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of such subsection. 

(c)    The Company is not a guarantor or indemnitor of any indebtedness of any other Person. 

2.11    Certain Transactions. 

(a)    Other than (i) standard employee benefits generally made available to all employees, (ii) standard
director and officer indemnification agreements approved by the Board of Directors, and (iii) the purchase of shares of the Company’s capital stock and the issuance of options to purchase shares of the Company’s Common Stock, in each
instance, approved in the written minutes of the Board of Directors (previously provided to the Purchasers or their counsel), there are no agreements, understandings or proposed transactions between the Company and any of its officers, directors,
consultants or Key Employees, or any Affiliate thereof. 
 (b)    The Company is not indebted, directly or indirectly,
to any of its directors, officers or employees or to their respective spouses or children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred in the ordinary course of business or
employee relocation expenses and for other customary employee benefits made generally available to all employees. None of the Company’s directors, officers or employees, or any members of their immediate families, or any Affiliate of the
foregoing are, directly or indirectly, indebted to the Company or, to the Company’s knowledge, have any (i) material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of the
Company’s customers, suppliers, service providers, joint venture partners, licensees and competitors, (ii) direct or indirect 

  
 7 














 
ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship, or any firm or corporation which competes with the
Company except that directors, officers, employees or stockholders of the Company may own stock in (but not exceeding two percent (2%) of the outstanding capital stock of) publicly traded companies that may compete with the Company; or
(iii) financial interest in any contract with the Company. 
 2.12    Rights of Registration and Voting
Rights. Except as provided in the Investors’ Rights Agreement, the Company is not under any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion
of its currently outstanding securities. To the Company’s knowledge, except as contemplated in the Voting Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company. 

2.13    Property. The property and assets that the Company owns are free and clear of all mortgages, deeds of
trust, liens, loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and do not materially impair the Company’s
ownership or use of such property or assets. With respect to the property and assets it leases, the Company is in compliance with such leases and holds a valid leasehold interest free of any liens, claims or encumbrances other than those of the
lessors of such property or assets. The Company does not own any real property. 
 2.14    Financial Statements.
The Company has made available to each Purchaser its unaudited financial statements (including balance sheet, income statement and statement of cash flows) as of December 31, 2018 and for the fiscal year ended December 31, 2018, and its unaudited
financial statements (including balance sheet, income statement and statement of cash flows) as of July 31, 2019 (the “Balance Sheet Date”) and for the seven-month period ended July 31, 2019 (collectively, the “Financial
Statements”). The Financial Statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) applied on a consistent basis throughout the periods indicated, except that the Financial Statements
may not contain all footnotes required by GAAP. The Financial Statements fairly present in all material respects the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject to normal year-end adjustments. Except as specifically set forth in the Financial Statements, the Company has no liability or obligation, absolute or contingent (individually or in the aggregate) or otherwise, except
(i) obligations and liabilities incurred after the Balance Sheet Date in the ordinary course of business, and (ii) obligations and liabilities under Contracts made in the ordinary course of business that would not be required under GAAP to
be reflected in the Financial Statements. The Company maintains and will continue to maintain a standard system of accounting established and administered in accordance with GAAP, consistently applied. The fiscal year of the Company begins on
January 1 of each calendar year and ends on December 31 of each calendar year. 
 2.15    Changes. Since the
Balance Sheet Date, there has not been: 
 (a)    any change in the assets, liabilities, financial condition or
operating results of the Company from that reflected in the Financial Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect; 

(b)    any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 (c)    any waiver or compromise by the Company of a valuable right or of a material debt owed to it; 

  
 8 














 (d)    any satisfaction or discharge of any lien, claim, or encumbrance
or payment of any obligation by the Company, except in the ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect; 

(e)    any material change to a material contract or agreement by which the Company or any of its assets is bound or
subject; 
 (f)    any material change in any compensation arrangement or agreement with any employee, officer, director
or stockholder; 
 (g)    any resignation or termination of employment of any officer or Key Employee of the Company;

 (h)    any mortgage, pledge, transfer of a security interest in, or lien, created by the Company, with respect to any
of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use of such property or assets; 

(i)    any loans or guarantees made by the Company to or for the benefit of its employees, officers or directors, or any
members of their immediate families, other than travel advances and other advances made in the ordinary course of its business; 

(j)    any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital
stock, or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company; 

(k)    any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result
in a Material Adverse Effect; 
 (l)    receipt of notice that there has been a loss of, or material order cancellation
by, any major customer of the Company; 
 (m)    to the Company’s knowledge, any other event or condition of any
character, other than events affecting the economy or the Company’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or 

(n)    any arrangement or commitment by the Company to do any of the things described in this Subsection 2.15. 

2.16    Employee Matters. 

(a)    To the Company’s knowledge, none of its employees is obligated under any contract (including licenses,
covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of the Company
or that would conflict with the Company’s business. Neither the execution or delivery of the Transaction Agreements, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s
business as now conducted and as presently proposed to be conducted, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or
instrument under which any such employee is now obligated. 

  
 9 














 (b)    The Company is not delinquent in payments to any of its
employees, consultants, or independent contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants or
independent contractors. The Company has complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker
classification and collective bargaining. The Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of the Company
and is not liable for any arrears of wages, taxes, penalties or other sums for failure to comply with any of the foregoing. 

(c)    To the Company’s knowledge, no Key Employee intends to terminate employment with the Company or is otherwise
likely to become unavailable to continue as a Key Employee. The Company does not have a present intention to terminate the employment of any of the foregoing. The employment of each employee of the Company is terminable at the will of the Company.
Except as set forth in Subsection 2.16(c) of the Disclosure Schedule or as required by law, upon termination of the employment of any such employees, no severance or other payments will become due. Except as set forth in Subsection 2.16(c) of the
Disclosure Schedule, the Company has no policy, practice, plan or program of paying severance pay or any form of severance compensation in connection with the termination of employment services. 

(d)    The Company has not made any representations regarding equity incentives to any officer, employee, director or
consultant that are inconsistent with the share amounts and terms set forth in the minutes of meetings of the Company’s board of directors. 

(e)    Each former Key Employee whose employment was terminated by the Company has entered into an agreement with the
Company providing for the full release of any claims against the Company or any related party arising out of such employment. 

(f)    Subsection 2.16(f) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or
sponsored by the Company, or which the Company participates in or contributes to, which is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The Company has made all required contributions and has
no liability to any such employee benefit plan, other than liability for health plan continuation coverage described in Part 6 of Title I(B) of ERISA, and has complied in all material respects with all applicable laws for any such employee benefit
plan. 
 (g)    The Company is not bound by or subject to (and none of its assets or properties is bound by or subject
to) any written or oral, express or implied, contract, commitment or arrangement with any labor union, and no labor union has requested or, to the knowledge of the Company, has sought to represent any of the employees, representatives or agents of
the Company. There is no strike or other labor dispute involving the Company pending, or to the Company’s knowledge, threatened, which could have a Material Adverse Effect, nor is the Company aware of any labor organization activity involving
its employees. 
 (h)    To the Company’s knowledge, none of the Key Employees or directors of the Company has
been (A) subject to voluntary or involuntary petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer by a court for his or her business or property;
(B) convicted in a criminal proceeding or named as a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (C) subject to any order, judgment or decree (not subsequently reversed, suspended, or
vacated) of any court of competent 

  
 10 














 
jurisdiction permanently or temporarily enjoining him or her from engaging, or otherwise imposing limits or conditions on his or her engagement in any securities, investment advisory, banking,
insurance, or other type of business or acting as an officer or director of a public company; or (D) found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading
Commission to have violated any federal or state securities, commodities, or unfair trade practices law, which such judgment or finding has not been subsequently reversed, suspended, or vacated. 

2.17    Tax Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by
the Company which have not been timely paid. There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax
returns or reports by any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect no
waivers of applicable statutes of limitations with respect to taxes for any year. 
 2.18    Insurance. The
Company has in full force and effect insurance policies concerning such casualties as would be reasonable and customary for companies like the Company with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to
replace any of its properties that might be damaged or destroyed. 
 2.19    Employee Agreements. Each current
and former employee, consultant and officer of the Company has executed an agreement with the Company regarding confidentiality and proprietary information substantially in the form or forms delivered to the counsel for the Purchasers (the
“Confidential Information Agreements”). No current or former Key Employee has excluded works or inventions from his or her assignment of inventions pursuant to such Key Employee’s Confidential Information Agreement. Each
current and former Key Employee has executed a non-competition and non-solicitation agreement substantially in the form or forms delivered to counsel for the Purchasers.
The Company is not aware that any of its Key Employees is in violation of any agreement covered by this Subsection 2.19. 

2.20    Permits. The Company has all franchises, permits, licenses and any similar authority necessary for the
conduct of its business, the lack of which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any material respect under any of such franchises, permits, licenses or other similar authority. 

2.21    Corporate Documents. The Restated Certificate and Bylaws of the Company are in the form provided to the
Purchasers. The copy of the minute books of the Company provided to the Purchasers contains minutes of all meetings of directors and stockholders and all actions by written consent without a meeting by the directors and stockholders since the date
of incorporation and accurately reflects in all material respects all actions by the directors (and any committee of directors) and stockholders with respect to all transactions referred to in such minutes. 

2.22    Environmental and Safety Laws. Except as could not reasonably be expected to have a Material Adverse Effect
to the best of its knowledge (a) the Company is and has been in compliance with all Environmental Laws; (b) there has been no release or to the Company’s knowledge threatened release of any pollutant, contaminant or toxic or hazardous
material, substance or waste or petroleum or any fraction thereof (each a “Hazardous Substance”), on, upon, into or from any site currently or heretofore owned, leased or otherwise used by the Company; (c) there have been no
Hazardous Substances generated by the Company that have been disposed of or come to rest at any site that has been included in any published U.S. federal, state or local “superfund” site list or any other similar list of hazardous or toxic
waste sites published by any governmental authority in the United 

  
 11 














 
States; and (d) there are no underground storage tanks located on, no polychlorinated biphenyls (“PCBs”) or PCB-containing equipment
used or stored on, and no hazardous waste as defined by the Resource Conservation and Recovery Act, as amended, stored on, any site owned or operated by the Company, except for the storage of hazardous waste in compliance with Environmental Laws.
The Company has made available to the Purchasers true and complete copies of all material environmental records, reports, notifications, certificates of need, permits, pending permit applications, correspondence, engineering studies and
environmental studies or assessments. 
 For purposes of this Subsection 2.22, “Environmental Laws” means any law,
regulation, or other applicable requirement relating to (a) releases or threatened release of Hazardous Substance; (b) pollution or protection of employee health or safety, public health or the environment; or (c) the manufacture,
handling, transport, use, treatment, storage, or disposal of Hazardous Substances. 
 2.23    Disclosure. The
Company has made available to the Purchasers all the information reasonably available to the Company that the Purchasers have requested for deciding whether to acquire the Shares. No representation or warranty of the Company contained in this
Agreement, as qualified by the Disclosure Schedule, and no certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material fact or, to the Company’s knowledge, omits to state a material fact
necessary in order to make the statements contained herein or therein not misleading in light of the circumstances under which they were made. The Business Plan was prepared in good faith; however, the Company does not warrant that it will achieve
any results projected in the Business Plan. 
 2.24    Foreign Corrupt Practices Act. Neither the Company nor any
of its subsidiaries nor any of their respective directors, officers, employees or agents have, directly or indirectly, made, offered, promised or authorized any payment or gift of any money or anything of value to or for the benefit of any
“foreign official” (as such term is defined in the U.S. Foreign Corrupt Practices Act of 1977, as amended (the “FCPA”)), foreign political party or official thereof or candidate for foreign political office for the purpose
of (i) influencing any official act or decision of such official, party or candidate, (ii) inducing such official, party or candidate to use his, her or its influence to affect any act or decision of a foreign governmental authority, or
(iii) securing any improper advantage, in the case of (i), (ii) and (iii) above in order to assist the Company or any of its affiliates in obtaining or retaining business for or with, or directing business to, any person. Neither the
Company nor any of its subsidiaries nor any of their respective directors, officers, employees or agents have made or authorized any bribe, rebate, payoff, influence payment, kickback or other unlawful payment of funds or received or retained any
funds in violation of any law, rule or regulation. The Company further represents that it has maintained, and has caused each of its subsidiaries and affiliates to maintain, systems of internal controls (including, but not limited to, accounting
systems, purchasing systems and billing systems) and written policies to ensure compliance with the FCPA or any other applicable anti-bribery or anti-corruption law, and to ensure that all books and records of the Company and its subsidiaries
accurately and fairly reflect, in reasonable detail, all transactions and dispositions of funds and assets. Neither the Company nor, to the Company’s knowledge, any of its officers, directors or employees are the subject of any allegation,
voluntary disclosure, investigation, prosecution or other enforcement action related to the FCPA or any other anti-corruption law (collectively, “Enforcement Action”). 

2.25    Company Valuation. The Company is not aware of any facts or circumstances that would reasonably be expected
to cause the valuation of the Company to be less than $65,530,000. 
 2.26    Special Redemption Right. As of the
date of the Initial Closing, the Company is not aware of any fact and/or circumstance that could avoid the application of the “Special Redemption Right” set forth in Section 4.3.6 of the Restated Certificate. 

  
 12 














 3.    Representations and Warranties of the Purchasers. Each
Purchaser hereby represents and warrants to the Company, severally and not jointly, that: 
 3.1    Authorization.
The Purchaser has full power and authority to enter into the Transaction Agreements. The Transaction Agreements to which the Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of
the Purchaser, enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance and any other laws of general application affecting enforcement of
creditors’ rights generally, and as limited by laws relating to the availability of specific performance, injunctive relief or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Investors’
Rights Agreement may be limited by applicable federal or state securities laws. 
 3.2    Purchase Entirely for Own
Account. This Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to be acquired by
the Purchaser will be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any part thereof, and that the Purchaser has no present intention of selling,
granting any participation in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell,
transfer or grant participations to such Person or to any third Person, with respect to any of the Shares. The Purchaser has not been formed for the specific purpose of acquiring the Shares. 

3.3    Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business,
management, financial affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an opportunity to review the Company’s facilities. The foregoing, however, does not limit or modify the
representations and warranties of the Company in Section 2 of this Agreement or the right of the Purchasers to rely thereon. 

3.4    Restricted Securities. The Purchaser understands that the Shares have not been, and will not be, registered
under the Securities Act, by reason of a specific exemption from the registration provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s
representations as expressed herein. The Purchaser understands that the Shares are “restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Shares
indefinitely unless they are registered with the Securities and Exchange Commission and qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Company
has no obligation to register or qualify the Shares, or the Common Stock into which it may be converted, for resale except as set forth in the Investors’ Rights Agreement. The Purchaser further acknowledges that if an exemption from
registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of sale, the holding period for the Shares, and on requirements relating to the Company which are outside of
the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. 

3.5    No Public Market. The Purchaser understands that no public market now exists for the Shares, and that the
Company has made no assurances that a public market will ever exist for the Shares. 

  
 13 














 3.6    Legends. The Purchaser understands that the Shares and any
securities issued in respect of or exchange for the Shares, may be notated with one or all of the following legends: 
 “THE SHARES REPRESENTED HEREBY
HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION
STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT OF 1933.” 

(a)    Any legend set forth in, or required by, the other Transaction Agreements. 

(b)    Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares
represented by the certificate, instrument, or book entry so legended. 
 3.7    Accredited Investor. The
Purchaser is an accredited investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 

3.8    Foreign Investors. If the Purchaser is not a United States person (as defined by Section 7701(a)(30) of
the Code), the Purchaser hereby represents that it has satisfied itself as to the full observance of the laws of its jurisdiction in connection with any invitation to subscribe for the Shares or any use of this Agreement, including (i) the
legal requirements within its jurisdiction for the purchase of the Shares, (ii) any foreign exchange restrictions applicable to such purchase, (iii) any governmental or other consents that may need to be obtained, and (iv) the income
tax and other tax consequences, if any, that may be relevant to the purchase, holding, redemption, sale, or transfer of the Shares. The Purchaser’s subscription and payment for and continued beneficial ownership of the Shares will not violate
any applicable securities or other laws of the Purchaser’s jurisdiction. 
 3.9    No General Solicitation.
Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including, through a broker or finder (a) engaged in any general solicitation, or (b) published any
advertisement in connection with the offer and sale of the Shares. 
 3.10    Exculpation Among Purchasers. The
Purchaser acknowledges that it is not relying upon any Person, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. The Purchaser agrees that neither any Purchaser nor the respective
controlling Persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore taken or omitted to be taken by any of them in connection with the purchase of the Shares.

 3.11    Residence. If the Purchaser is an individual, then the Purchaser resides in the state or province
identified in the address of the Purchaser set forth on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of the Purchaser in which its principal place of business
is identified in the address or addresses of the Purchaser set forth on Exhibit A. 

  
 14 














 4.    Conditions to the Purchasers’ Obligations at Closing.
The obligations of each Purchaser to purchase Shares at the Initial Closing or any subsequent Closing are subject to the fulfillment, on or before such Closing, of each of the following conditions, unless otherwise waived: 

4.1    Representations and Warranties. The representations and warranties of the Company contained in
Section 2 shall be true and correct in all respects as of such Closing. 

4.2    Performance. The Company shall have performed and complied with all covenants, agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by the Company on or before such Closing. 

4.3    Compliance Certificate. The President of the Company shall deliver to the Purchasers at such Closing a
certificate certifying that the conditions specified in Subsections 4.1 and 4.2 have been fulfilled. 

4.4    Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory
body of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be obtained and effective as of such Closing. 

4.5    Board of Directors. As of the Initial Closing, the authorized size of the Board shall be increased by one,
and the Board shall be comprised of Maurizio Chiriva-Internati, Scott Dahlbeck, Peter Hoang, Gianluca Rotino, Jason Terrell, and one additional person to be designated by a majority of the holders of record of shares of Series B Preferred Stock with
a purchase price of at least $1,000,000 immediately following the Initial Closing. 
 4.6    Investors’ Rights
Agreement. The Company and each Purchaser shall have executed and delivered the Investors’ Rights Agreement. 

4.7    Right of First Refusal and Co-Sale Agreement. The Company, each
Purchaser and the other stockholders of the Company named as parties thereto shall have executed and delivered the Right of First Refusal and Co-Sale Agreement. 

4.8    Voting Agreement. The Company, each Purchaser (other than the Purchaser relying upon this condition to excuse
such Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto shall have executed and delivered the Voting Agreement. 

4.9    Restated Certificate. The Company shall have filed the Restated Certificate with the Secretary of State of
Delaware on or prior to the Closing, which shall continue to be in full force and effect as of the Closing. 

4.10    Secretary’s Certificate. The Secretary of the Company shall have delivered to the Purchasers at the
Closing a certificate certifying (i) the Bylaws of the Company, (ii) resolutions of the Board of Directors of the Company approving the Transaction Agreements and the transactions contemplated under the Transaction Agreements, and
(iii) resolutions of the stockholders of the Company approving the Restated Certificate. 
 4.11    Proceedings
and Documents. All corporate and other proceedings in connection with the transactions contemplated at the Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser, and each Purchaser
(or its counsel) shall have received all such counterpart original and certified or other copies of such documents as reasonably requested. Such documents may include good standing certificates. 

  
 15 














 4.12    Preemptive Rights. The Company shall have fully satisfied
(including with respect to rights of timely notification) or obtained enforceable waivers in respect of any preemptive or similar rights directly or indirectly affecting any of its securities. 

4.13    Warrant. The Company shall have delivered to each Purchaser acquiring Shares at the Initial Closing with an
aggregate purchase price in excess of $1,000,000 a warrant in the form and substance of the Form of Warrant attached as Exhibit G. 

5.    Conditions of the Company’s Obligations at Closing. The obligations of the Company to sell Shares to the
Purchasers at the Initial Closing or any subsequent Closing are subject to the fulfillment, on or before the Closing, of each of the following conditions, unless otherwise waived: 

5.1    Representations and Warranties. The representations and warranties of each Purchaser contained in
Section 3 shall be true and correct in all respects as of such Closing. 

5.2    Performance. The Purchasers shall have performed and complied with all covenants, agreements, obligations and
conditions contained in this Agreement that are required to be performed or complied with by them on or before such Closing. 

5.3    Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory
body of the United States or of any state that are required in connection with the lawful issuance and sale of the Shares pursuant to this Agreement shall be obtained and effective as of the Closing. 

5.4    Investors’ Rights Agreement. Each Purchaser shall have executed and delivered the Investors’ Rights
Agreement. 
 5.5    Right of First Refusal and Co-Sale Agreement. Each
Purchaser and the other stockholders of the Company named as parties thereto shall have executed and delivered the Right of First Refusal and Co-Sale Agreement. 

5.6    Voting Agreement. Each Purchaser and the other stockholders of the Company named as parties thereto shall
have executed and delivered the Voting Agreement. 
 6.    Miscellaneous. 

6.1    Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of
the Company and the Purchasers contained in or made pursuant to this Agreement shall survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof
made by or on behalf of the Purchasers or the Company. 
 6.2    Successors and Assigns. The terms and conditions
of this Agreement shall inure to the benefit of and be binding upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their
respective successors and assigns any rights, remedies, obligations or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

6.3    Governing Law. This Agreement shall be governed by and construed in accordance with the internal laws of the
State of Delaware, without giving effect to any choice or conflict of law provision or rule (whether of the State of Delaware or any other jurisdiction) that would cause the application of laws of any jurisdiction other than those of the State of
Delaware (the “Governing Law”). 

  
 16 














 6.4    Counterparts. This Agreement may be executed in two
(2) or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature
complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. 

6.5    Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are
not to be considered in construing or interpreting this Agreement. 
 6.6    Notices. All notices and other
communications given or made pursuant to this Agreement or any Transaction Agreement shall be in writing shall be delivered both physically and via electronic mail and shall be deemed effectively given upon the earlier of actual receipt, or
(a) personal delivery to the party to be notified, (b) when sent, if sent by electronic mail or facsimile during normal business hours of the recipient, and if not sent during normal business hours, then on the recipient’s next
business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) business day after deposit with a nationally recognized overnight courier, freight prepaid,
specifying next business day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their e-mail address and mailing address as set forth on the signature page or Exhibit A, or to such e-mail address, facsimile number or address as subsequently modified by written notice given in accordance with this Subsection 6.6. All notices to the Company shall be addressed as follows: 

Kiromic, Inc. 
 Fannin
South Professional Building 
 7707 Fannin, St Suite 140 

Houston, Texas 77054 
 Attn: Scott
Dahlbeck 
 Phone: (713) 689-4450 

Email: sdahlbeck@kiromic.com 
 a copy (which
shall not constitute notice) shall also be sent physically and via e-mail to: 
 Norton Rose Fulbright 

1301 McKinney St., Suite 5100, 

Houston, Texas 77010, 
 Attn:
Charles Powell 
 charles.powell@nortonrosefulbright.com 

If notice is given to the Investors, copies (which shall not constitute notice) shall also be sent physically and via
e-mail to: 
 Avv. Giovanni Meliadò 

Roma 
 Via G. Vico n.1 - 00196
Roma 
 avv.meliado@gmail.com 

Avv. Laura Porta 

  
 17 














 6.7    No Finder’s Fees. Each party represents that it
neither is nor will be obligated for any finder’s fee or commission in connection with this transaction. Each Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or compensation in the nature of
a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which each Purchaser or any of its officers, employees or representatives is responsible.
The Company agrees to indemnify and hold harmless each Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending
against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

6.8    Amendments and Waivers. The terms of this Agreement may be amended, terminated or waived only with the
written consent of the Company and the holders of not less than 66.7% of the shares of Common Stock issued or issuable upon conversion of the then-outstanding Shares or (ii) for an amendment, termination or waiver effected prior to the Closing,
Purchasers obligated to purchase not less than 66.7% of the Shares to be issued at the Closing. Any amendment or waiver effected in accordance with this Section 6.9 shall be binding upon the Purchasers and each transferee of the Shares (or the
Common Stock issuable upon conversion thereof), each future holder of all such securities, and the Company. 

6.9    Severability. The invalidity or unenforceability of any provision hereof shall in no way affect the validity
or enforceability of any other provision. 
 6.10    Delays or Omissions. No delay or omission to exercise any
right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any
single breach or default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement,
or any waiver on the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or
otherwise afforded to any party, shall be cumulative and not alternative. 
 6.11    Entire Agreement. This
Agreement (including the Exhibits hereto), the Restated Certificate and the other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written
or oral agreement relating to the subject matter hereof existing between the parties are expressly canceled. 

6.12    Termination of Closing Obligations. Each Purchaser shall have the right to terminate its obligations to
complete the Initial Closing or the Second Closing, as the case may be, if prior to the occurrence thereof, any of the following occurs: 

(a)    the Company consummates a Deemed Liquidation Event (as defined in the Restated Certificate); 

  
 18 














 (b)    the closing of an initial public offering of the Company, in
which case the Purchasers may terminate their obligations hereunder immediately prior to, or contingent upon, such closing; or 

(c)    the Company (i) applies for or consents to the appointment of a receiver, trustee, custodian or liquidator of
itself or substantially all of its property, (ii) becomes subject to the appointment of a receiver, trustee, custodian or liquidator of itself or substantially all of its property, (iii) makes an assignment for the benefit of creditors,
(iv) institutes any proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, or files a petition or
answer seeking reorganization or an arrangement with creditors to take advantage of any insolvency law, or files an answer admitting the material allegations of a bankruptcy, reorganization or insolvency petition filed against it, or
(v) becomes subject to any involuntary proceedings under the United States Bankruptcy Code or any other federal or state bankruptcy, reorganization, receivership, insolvency or other similar law affecting the rights of creditors generally, when
proceeding is not dismissed within thirty (30) days of filing, or have an order for relief entered against it in any proceedings under the United States Bankruptcy Code. 

6.13    Dispute Resolution. All disputes arising out of or in connection with this Agreement shall be finally
settled under the Rules of Arbitration of the International Chamber of Commerce by one or more arbitrators appointed in accordance with the said Rules. Any such arbitration shall (i) be subject to the application of the Governing Law,
(ii) take place in Paris, France and (iii) be conducted in English. Each of the parties to this Agreement consents to personal jurisdiction for any emergency injunction sought in the U.S. District Court for the Southern District of Texas
or any court of the State of Texas having subject matter jurisdiction. However, subsequent to the emergency injunction hearing, the merits of the matter will be decided by the ICC as per the procedure set forth above. The Company hereby consents to
the resolution pursuant to and in accordance with this Section 6.13 of any dispute between the Company and any Purchaser arising under any provision related to the preferences, privileges, or other rights of holders of
Series B Preferred Stock set forth in the Restated Certificate. 
 6.14    No Commitment for Additional
Financing. The Company acknowledges and agrees that no Purchaser has made any representation, undertaking, commitment or agreement to provide or assist the Company in obtaining any financing, investment or other assistance, other than the
purchase of the Shares as set forth herein and subject to the conditions set forth herein. In addition, the Company acknowledges and agrees that (i) no statements, whether written or oral, made by any Purchaser or its representatives on or
after the date of this Agreement shall create an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment, (ii) the Company shall not rely on any such statement by any Purchaser or its
representatives, and (iii) an obligation, commitment or agreement to provide or assist the Company in obtaining any financing or investment may only be created by a written agreement, signed by such Purchaser and the Company, setting forth the
terms and conditions of such financing or investment and stating that the parties intend for such writing to be a binding obligation or agreement. Each Purchaser shall have the right, in its sole and absolute discretion, to refuse or decline to
participate in any other financing of or investment in the Company, and shall have no obligation to assist or cooperate with the Company in obtaining any financing, investment or other assistance. 

  
 19 














 IN WITNESS WHEREOF, the parties have executed this Series B Preferred Stock Purchase
Agreement as of the date first written above. 
  

			
	COMPANY:
		
	By:	 	/s/ Maurizio Chiriva Internati
		
	Name:	 	Maurizio Chiriva Internati
		 	(print)
		
	Title:	 	Chief Executive Officer
	
	Address: